显示标签为“CRISPR”的博文。显示所有博文
显示标签为“CRISPR”的博文。显示所有博文

2016年3月14日星期一

CRISPR tells us that gene editing is just the beginning

On March 7th, the website of the journal Nature published an article entitled article "CRISPR gene editing is just the beginning", pointing out that gene editing is only a starting point of CRISPR technology application. The real ability of this biological tool in these feature stories in Nature is to explore the operational mechanism of the genome. And it introduced technological achievements and applications published on Nature, Science, Cell and their sub-journals recently.

Epigenetic modification on DNA is not the only genome code to be cracked. Over 98% of the human genome does not encode proteins. But the researchers believe that a considerable part of such DNA doing important things, they are adopting CRISPR-Cas9 to clarify what it is.

Some DNA encoding such as microRNAs and long non-coding RNA molecule of a class - people think they have a function other than protein synthesis. Other sequences can be required to enlarge the gene expression "enhancers." Most common risks associated with the DNA sequence located in the genomic region containing the non-coding RNA and enhancers in. But before CRISPR-Cas9, researchers were difficult to figure out the function of these sequences. Boston Children's Hospital hematologist Daniel Bauer said, "We do not have a good way of these non-coding genomic annotation from the feature is now more sophisticated in our experiments."

University of Southern California molecular biologist Peggy Farnham and colleagues used CRISPR-Cas9 delete mutations in prostate cancer and colorectal cancer genome research found enhancer region. Sometimes the findings surprised her. In an experiment not released, her team deleted a past that is important enhancer, not its one million bases in a gene expression changes. "It happened when we usually classify a regulatory element influence the way you remove the element and does not match."

When possible use of CRISPR-Cas9 researchers to explore the large fragment of DNA regulation will be more surprises. From the Massachusetts Institute of Technology (MIT) genetic David Gifford and Brigham and Women's Hospital research team led by Richard Sherwood advantage of this technology in the base sequence of some 40,000 manufacturing mutation, then examined whether each change would near fluorescent protein coding genes affected. Thereby resulting in a DNA sequence to enhance gene expression profiles, including several based on characteristics such as gene regulation chromatin modification is not predicted sequence (CRISPR NEW, Looking for gene regulatory elements, High-throughput mapping of regulatory DNA.Nature Biotechnology 34, 167-174 (2016) doi: 10.1038 / nbt.3468).

In-depth study of this dark matter is faced with challenges even using CRISPR-Cas9. Cas9 wizard RNA cleavage enzyme will inform its site, but only if there is a specific and near the common DNA sequence cleavage site. Researchers who want to silence the gene is not difficult, because these important sequences are almost always exists somewhere within the gene. But for those who want to complete a short non-coding RNAs are very specific changes for the limited choice. Netherlands Cancer Institute researcher Reuven Agami, said, "We cannot get any sequence."

We recommend this for you: http://www.cusabio.com/ELISA-Kit/Bovine-C-telopeptide-of-type-%E2%85%A1-collagenCTX-%E2%85%A1-ELISA-Kit-1035497.html

CRISPR tells us that gene editing is just the beginning

On March 7th, the website of the journal Nature published an article entitled article "CRISPR gene editing is just the beginning", pointing out that gene editing is only a starting point of CRISPR technology application. The real ability of this biological tool in these feature stories in Nature is to explore the operational mechanism of the genome. And it introduced technological achievements and applications published on Nature, Science, Cell and their sub-journals recently.

Epigenetic modification on DNA is not the only genome code to be cracked. Over 98% of the human genome does not encode proteins. But the researchers believe that a considerable part of such DNA doing important things, they are adopting CRISPR-Cas9 to clarify what it is.

Some DNA encoding such as microRNAs and long non-coding RNA molecule of a class - people think they have a function other than protein synthesis. Other sequences can be required to enlarge the gene expression "enhancers." Most common risks associated with the DNA sequence located in the genomic region containing the non-coding RNA and enhancers in. But before CRISPR-Cas9, researchers were difficult to figure out the function of these sequences. Boston Children's Hospital hematologist Daniel Bauer said, "We do not have a good way of these non-coding genomic annotation from the feature is now more sophisticated in our experiments."

University of Southern California molecular biologist Peggy Farnham and colleagues used CRISPR-Cas9 delete mutations in prostate cancer and colorectal cancer genome research found enhancer region. Sometimes the findings surprised her. In an experiment not released, her team deleted a past that is important enhancer, not its one million bases in a gene expression changes. "It happened when we usually classify a regulatory element influence the way you remove the element and does not match."

When possible use of CRISPR-Cas9 researchers to explore the large fragment of DNA regulation will be more surprises. From the Massachusetts Institute of Technology (MIT) genetic David Gifford and Brigham and Women's Hospital research team led by Richard Sherwood advantage of this technology in the base sequence of some 40,000 manufacturing mutation, then examined whether each change would near fluorescent protein coding genes affected. Thereby resulting in a DNA sequence to enhance gene expression profiles, including several based on characteristics such as gene regulation chromatin modification is not predicted sequence (CRISPR NEW, Looking for gene regulatory elements, High-throughput mapping of regulatory DNA.Nature Biotechnology 34, 167-174 (2016) doi: 10.1038 / nbt.3468).

In-depth study of this dark matter is faced with challenges even using CRISPR-Cas9. Cas9 wizard RNA cleavage enzyme will inform its site, but only if there is a specific and near the common DNA sequence cleavage site. Researchers who want to silence the gene is not difficult, because these important sequences are almost always exists somewhere within the gene. But for those who want to complete a short non-coding RNAs are very specific changes for the limited choice. Netherlands Cancer Institute researcher Reuven Agami, said, "We cannot get any sequence."

We recommend this for you: http://www.cusabio.com/ELISA-Kit/Bovine-C-telopeptide-of-type-%E2%85%A1-collagenCTX-%E2%85%A1-ELISA-Kit-1035497.html

2016年1月15日星期五

Does powerful gene editing tool CRISPR really help treat diseases?

Does powerful editing tool CRISPR really help treat diseases? There are a lot of pharmaceutical companies racing to find the answers.

Recently, Bayer AG announced a joint venture with startups CRISPR Therapeutics for the treatment of three hundred million US dollars to develop drugs for blood disorders, blindness, congenital heart diseases. This is just the pharmaceutical industry eager to take advantage of the first signs of CRISPR find and develop new methods of treatment. However, fully grasp the CRISPR tool to develop the full potential of the drug is still too early, will focus on recent developments in the CRISP system uses to edit specific condition to go.

CRISPR Therapeutics is one of three high-profile start-up companies, the other two are Editas Medicine and Intellia Therapeutics. They hope to use CRISPR gene editing tools to develop new drugs. All three companies are working with a large pharmaceutical manufacturing company has won or investment transactions in the past year has revealed broad areas of disease drug manufacturers see opportunities for the application of new tools.

In the short term, CRISPR's use in some genetic diseases or cancer cases may be more attractive. These therapies mean removing the body cells, modifying their DNA, and reintroducing them. However, the three companies are also interested in the development of technology to deliver CRISPR cells in the body, without removing it. This will be a more complex challenge.

A major goal of Bayer and CRISPR Therapeutics create the joint venture is to develop new transmission technology, which is the future of drug development in vivo cell is the "key", Rodger Novak, CEO of CRISPR Therapeutics. This is not a small challenge. In order to work, the drug must first find a suitable organ or tissue. Once it's there, it must be a safe way to put payloads into the correct cells.

You may like to read this: http://www.cusabio.com/ELISA-Kit/Goat-vitamin-B12-VB12-ELISA-kit-1042287.html